Abstract
The hepatitis B virus infection is a public health problem. Treatment-naïve individuals with HBeAg reagents and not cirrhotic are indicated to use Tenovovir (TDF) as the first choice. Acute kidney injury and insipidus diabetes have already been reported as consequence of Tenofovir use. In addition, there are descriptions of renal proximal tubular (RPT) injury with characteristics similar …